These agents were also shown to significantly decrease hypoxia-induced HIF-1α protein expression, DNA binding, and transcription activity in human glioblastoma and prostate cancer cells, suppressing their migration and invasion [38,39], and to sensitize rhabdomyosarcoma and Ewing’s sarcomas to TRAIL- or doxorubicin-induced apoptosis under hypoxia [37]. The gene discussed is TNFSF10; the disease is prostate cancer.